Trials / Active Not Recruiting
Active Not RecruitingNCT06504615
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
A French, Prospective, Observational, Multicenter Study of Patients Treated With Nivolumab Plus Chemotherapy as First Line Treatment in Advanced or Metastatic Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma or Gastric Adenocarcinoma [METAGIO]
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 208 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.
Conditions
- Gastric Adenocarcinoma
- Gastro-esophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma (EAC)
- Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab + chemotherapy | As prescribed by the treating clinician, as per product label |
Timeline
- Start date
- 2024-12-10
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
- First posted
- 2024-07-17
- Last updated
- 2026-04-03
Locations
2 sites across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06504615. Inclusion in this directory is not an endorsement.